BIA Networking Lunch - Nottingham
Register today for another popular networking lunch, hosted by BioCity Nottingham. This is a great opportunity to hear from local members, meet new business contacts and grab a bite to eat. We are excited to be showcasing members from BioCity and the Nottingham region.
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
Toby is Managing Director of BioCity Group which exists to provide the environment in which early and growing stage life sciences and healthcare companies are more likely to be successful.
Toby is responsible for creating and maintaining the environment to nurture the success of companies at the BioCity and MediCity sites. He also leads the accelerator programme activity across the group. Toby has been with BioCity for 6 years.
Previously, Toby ran a network of various funders and advisers, established to make business owners aware of the opportunities to raise finance and to collaborate to help get deals done. He consulted with HM Treasury on the Seed Enterprise Investment Scheme and has continually championed the role of early stage venture capital.
His career started in engineering and project management. After becoming chartered, he left engineering to start his first company in 2001 and since then he started and raised money for companies in financial services, digital media and business coaching, as well as mentoring and supporting a large range of other start-up companies across all sectors.
Professor Graham Ball
Prof Graham Ball is Professor of Bioinformatics at Nottingham Trent University and CSO of CompanDX Ltd. He is Associate Director the John Van Geest Cancer Research Centre and biostatistics lead on three clinical projects. He is a visiting professor at the University of Auvergne and at Nottingham University Hospitals Trust. He has been involved in the development and validation of bioinformatic algorithms using Artificial Neural Networks to identify robust biomarkers and key molecular drivers for the last 15 years. After a PhD (UN funded) and a Post Doc modelling environmental interactions with ANNs at NTU, in 2000 he shifted the focus of his analysis to proteomic and genomic data searching for proteins and genes associated with cancer. His current research interests are directed at the classification and characterisation of biological systems, identification of molecular drivers of disease and development of diagnostic and classification models through the use of ANNs and other machine learning techniques. Areas of interest include pan cancer studies, host response to infection and immune function in cancer. He has over 140 publications (many of 3* and 4* rating) and 3 patents in the field.
Professor Steven Chalton
Steven is co-founder and Chief Scientific Officer at Excellerate Bioscience Ltd, a CRO providing specialist molecular pharmacology solutions to the drug discovery sector. He is also Professor of Molecular Pharmacology and Drug Discovery at the University of Nottingham. Prior to these roles he spent 16 years in the pharmaceutical industry, both at SmithKline Beecham and Novartis. At Novartis he was Director of Molecular Pharmacology in Respiratory Diseases, leading an assay development and compound profiling team of 30 scientists providing expert opinion and support for GPCR, ion channel and enzyme projects. He has broad drug discovery experience, ranging from target validation through to leading full lead optimisation programmes to successful clinical proof of concept. He is interested in all aspects of the quantitative assessment of ligand-receptor interactions, with a particular interest in the kinetics of ligand binding and signalling. Prof Charlton was awarded Novartis Leading Scientist in 2007.
Discovery Building (New Build)
12:00 - 13:00 Registration, networking and lunch
13:00 - Welcome and BIA update, Steve Bates, BIA
13.10 - BioCity welcome and update, Toby Reid, BioCity Group
13.20 - Professor Graham Ball, CompanDx
13.40 - Professor Steven Chalton, Excellerate Bioscience
14:00 - 14:30 Further networking